Eric Ng
YOU?
Author Swipe
View article: <i>Sinorhizobium meliloti</i> BR-bodies promote fitness during host colonization
<i>Sinorhizobium meliloti</i> BR-bodies promote fitness during host colonization Open
Biomolecular condensates are non-membrane-bound assemblies of proteins and nucleic acids that facilitate specific cellular processes. Like eukaryotic P-bodies, the recently discovered bacterial ribonucleoprotein bodies (BR-bodies) organize…
View article: Using the theory of planned behavior to examine the environmental behavior of roadrunners in Taiwan
Using the theory of planned behavior to examine the environmental behavior of roadrunners in Taiwan Open
Background Road running and similar community events boost local economies but also generate significant disposable waste, raising environmental concerns. According to the Theory of Planned Behavior, eco-friendly intentions are influenced …
View article: Urgency to secure funding for the promised national school food program amidst the rise of food costs and chronic disease
Urgency to secure funding for the promised national school food program amidst the rise of food costs and chronic disease Open
An overwhelming number of Canadians believe that a national school food program (SFP) would benefit children, but concerns around limited funding are frequently raised. SFPs across Canada are struggling to meet increasing demands due to ri…
View article: Urgency to secure funding for the promised national school food program amidst the rise of food costs and chronic disease
Urgency to secure funding for the promised national school food program amidst the rise of food costs and chronic disease Open
An overwhelming number of Canadians believe that a national school food program (SFP) would benefit children, but concerns around limited funding are frequently raised. SFPs across Canada are struggling to meet increasing demands due to ri…
View article: <i>Sinorhizobium meliloti</i>BR-bodies promote fitness during host colonization
<i>Sinorhizobium meliloti</i>BR-bodies promote fitness during host colonization Open
Biomolecular condensates, such as the nucleoli or P-bodies, are non-membrane-bound assemblies of proteins and nucleic acids that facilitate specific cellular processes. Like eukaryotic P-bodies, the recently discovered bacterial ribonucleo…
View article: Vulnerability assessment of forest protected areas to environmental hazards
Vulnerability assessment of forest protected areas to environmental hazards Open
The aim of the present study was to investigate the vulnerability of Helen Forest protected area to multiple environmental hazards including drought, evapotranspiration, flood, landslide and wildfire. To this end, in the first stage, field…
View article: Influence of Landscape Preference and Place Attachment on Responsible Environmental Behavior—A Study of Taipei’s Guandu Nature Park Wetlands, Taiwan
Influence of Landscape Preference and Place Attachment on Responsible Environmental Behavior—A Study of Taipei’s Guandu Nature Park Wetlands, Taiwan Open
Wetlands provide important ecological services and aesthetic value at the landscape level. A landscape that makes people feel or appreciate the beauty of nature and is ecologically healthy and aesthetically beautiful can elicit positive em…
View article: 636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials Open
Background Chimeric antigen receptor (CAR) T-cell therapy has been challenging in solid tumors due to an absence of tumor-specific targets and the resultant on-target, off-tumor toxicity. Tmod, a novel logic-gated CAR T-cell therapy, utili…
View article: 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH) Open
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical efficacy in hematologic malignancies1; however, implementation of these therapies in solid tumors has been challenging due to a lack of tumor-specific targ…
View article: Supplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F parental antibody, 10D1P, binds with high affinity and specificity to a species-conserved epitope on HER3, and Class 1 and Class 2 HER3 antibodies show different HER3 binding profiles in presence and absence of NRG1
View article: Supplemental Table 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplemental Table 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplemental Table 3 - Toxicological data showing no adverse effects of 10D1F on the indicated hematological and biochemistry parameters in multiple rodent models
View article: Supplementary Figure 5 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 5 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1P demonstrates potent in vivo tumor growth inhibition in multiple xenograft tumor models
View article: Supplementary Material from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Material from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplementary Methods with References, Supplementary Figure Legends, and list of Supplementary Tables
View article: Supplementary Figure 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F demonstrates superior inhibition of cancer cell line proliferation by potently inhibiting downstream signaling through the PI3K pathway in additional cancer cell lines
View article: Data from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Data from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
In recent years, HER3 has increasingly been implicated in the progression of a variety of tumor types and in acquired resistance to EGFR and HER2 therapies. Whereas EGFR and HER2 primarily signal through the MAPK pathway, HER3, as a hetero…
View article: Supplementary Figure 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F demonstrates superior inhibition of cancer cell line proliferation by potently inhibiting downstream signaling through the PI3K pathway in additional cancer cell lines
View article: Supplementary Material from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Material from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplementary Methods with References, Supplementary Figure Legends, and list of Supplementary Tables
View article: Supplemental Table 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplemental Table 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplemental Table 1 - Summary of the published functional mechanisms of action for anti-HER3 neutralizing antibodies in development
View article: Supplementary Figure 5 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 5 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1P demonstrates potent in vivo tumor growth inhibition in multiple xenograft tumor models
View article: Supplementary Figure 4 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 4 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F does not show rapid internalization in HER3 expressing cancer cell lines but activates ADCC
View article: Supplemental Table 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplemental Table 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplemental Table 2 - Summary of protein and gene expression data of HER family molecules, and their ligands, for the cancer cell lines used in this study
View article: Supplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F parental antibody, 10D1P, binds with high affinity and specificity to a species-conserved epitope on HER3, and Class 1 and Class 2 HER3 antibodies show different HER3 binding profiles in presence and absence of NRG1
View article: Supplemental Table 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplemental Table 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplemental Table 1 - Summary of the published functional mechanisms of action for anti-HER3 neutralizing antibodies in development
View article: Supplemental Table 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplemental Table 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplemental Table 3 - Toxicological data showing no adverse effects of 10D1F on the indicated hematological and biochemistry parameters in multiple rodent models
View article: Supplemental Table 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplemental Table 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
Supplemental Table 2 - Summary of protein and gene expression data of HER family molecules, and their ligands, for the cancer cell lines used in this study
View article: Supplementary Figure 4 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 4 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F does not show rapid internalization in HER3 expressing cancer cell lines but activates ADCC
View article: Data from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Data from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
In recent years, HER3 has increasingly been implicated in the progression of a variety of tumor types and in acquired resistance to EGFR and HER2 therapies. Whereas EGFR and HER2 primarily signal through the MAPK pathway, HER3, as a hetero…
View article: Supplementary Figure 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Supplementary Figure 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models Open
10D1F interacts with linear peptides from the HER3 domain II dimerization interface